Glimison-MP 1 Tablet SR is a fixed-dose combination oral hypoglycemic agent containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which improves insulin sensitivity in adipose tissue, muscle, and the liver. The sustained-release formulation ensures a gradual and prolonged release of the active ingredients, promoting better patient compliance and stable plasma drug concentrations. Glimison-MP 1 Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy and is intended to be used alongside diet and exercise to achieve optimal glycemic control. It is essential to monitor renal and hepatic function periodically during treatment. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, weight gain, and edema. Proper medical supervision is advised during therapy.

Dosage & How to Use